Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx is positioned favorably because IBSRELA is still showing strong underlying demand, with 3Q revenue of $96.3M up 23% y/y, while management’s selective approach to rebates suggests access can improve without a broad pricing reset. The company also has meaningful operating leverage, given gross margins above 95%, a 3Q GAAP net loss of just $0.7M, and guidance to keep FY26 OpEx below $500M, supporting a clearer path to profitability as revenue scales. Longer term, reimbursement support, expanded pharmacy-network utilization, and the Phase 3 ACCEL program in 2H27 could broaden the addressable market, while the new patent scheduled to issue on November 10, 2026 adds durability to the tenapanor franchise.

Ardelyx is facing a deteriorating fundamental setup, as the resignation of Chief Commercial Officer Eric Foster effective August 28 removes a key commercial leader just as management reset guidance after the recent 2Q26 update. The company also faces reimbursement headwinds on multiple fronts, which can pressure adoption and limit the earnings leverage expected from IBSRELA and XPHOZAH even though script data for Ibsrela remains steady. On top of that, regulatory risk remains elevated because accelerated approval strategies may require additional data or longer studies, while any changes in reimbursement pricing structures could further reduce market traction.